Feb 22 |
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
|
Jan 31 |
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
|
Jan 29 |
Daré Bioscience announces executive team changes
|
Jan 26 |
Daré Bioscience to eliminate CFO and CCO roles to rein in costs
|
Jan 26 |
Daré Bioscience Announces Executive Team and Board of Directors Changes
|
Jan 17 |
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
|
Jan 10 |
Organon says Xaciato now available nationwide
|
Jan 4 |
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
|
Jan 4 |
When Will Daré Bioscience, Inc. (NASDAQ:DARE) Become Profitable?
|
Dec 26 |
Dare Bioscience secures $12M in royalty-backed investment structure
|